Take in Non-CME Industry Symposia at ATS 2015

The ATS encourages Non-CME Industry Symposia in conjunction with the International Conference. All full-conference participants are encouraged to attend these programs.


6:30 to 9 p.m.
Sheraton Denver Downtown: Majestic Ballroom (Tower Building; Majestic Level)
The Evolution of Clinical Management in PAH: Perspectives on Treatment
6:30 p.m. Registration & Buffet Dinner
7 to 9 p.m. Interactive Session

This dinner symposium will feature leading experts in PAH in an interactive and engaging discussion-based format. The faculty will explore the evolution of clinical management in PAH and perspectives in treatment approaches. Discussions will look at treatment goals, evidence-based decision-making, and current approaches to therapy. The session also will incorporate patient profiles and allow for audience participation. The program is open to all ATS 2015 International Conference attendees.

Speakers: David Badesch, MD, Chairperson, University of Colorado Health Sciences Center, Aurora, CO; Ioana Preston, MD, Tufts University School of Medicine, Boston, MA, and Sean M. Studer, MD, MSc, New York University Woodhull Medical Center, New York, NY

Company: Gilead Sciences, Inc.

6:30 to 9:30 p.m.
Embassy Suites Denver-Downtown Convention Center: Crystal Ballroom (3rd Floor)
Battle of the Minds: Diagnosing and Treating IPF

Put your knowledge about IPF to the test against your colleagues. Take the HRCT Challenge to improve your ability to recognize the important features of usual interstitial pneumonia associated with IPF. Then join an esteemed faculty panel for an engaging review of important information related to a branded therapy for IPF.

Speakers: Program Chairperson: Marilyn K. Glassberg, MD, Professor of Medicine, Surgery, and Pediatrics, Director, Rare and Interstitial Lung Disease Program, University of Miami, Miller School of Medicine, Miami; Distinguished Faculty: Ganesh Raghu, MD, FCCP, FACP, Professor of Medicine & Lab Medicine (Adjunct), Director, Center for Interstitial Lung Disease (ILD), ILD, Sarcoid and Pulmonary Fibrosis Program, University of Washington, Seattle; and Imre Noth, MD, Professor of Medicine, Director, Interstitial Lung Disease Program, The University of Chicago, Chicago

Company: Boehringer Ingelheim Pharmaceuticals, Inc.

6:30 to 9:30 p.m.
Embassy Suites Denver-Downtown Convention Center: Silverton Ballroom (2nd Floor)
Interactive Expert Forum: Identifying Best Practice in Antibiotic Use in
Non-CF Bronchiectasis

Interactive forum providing participants opportunities to discuss NCFB patients at-risk for exacerbations, focusing on treatment of chronic respiratory infections including those caused by Pseudomonas aeruginosa and/or nontuberculous mycobacteria. Collaborative exercises between experts and participants include polling and roundtable discussion allowing extensive dialogue on current practices of long-term NCFB management.

Company: Bayer Pharma AG

6:30 to 9:30 p.m.
Sheraton Denver Downtown: Grand Ballroom 2 (Tower Building; 2nd Level)
IPF: Considerations for Treatment

Join an esteemed faculty for a presentation and panel discussion on a treatment option for patients with IPF. This dinner symposia will include presentation of an overview of IPF, treatment considerations, and a patient case study.

Company: Genentech, Inc.

6:30 to 9:30 p.m.
Grand Hyatt Denver: Imperial Ballroom (2nd Floor)
A Patient-Centric Approach to Asthma Management

A distinguished panel will explore a patient-centric approach to asthma management, examining optimal and potential future personalized approaches. Treatment options for mild and severe asthma will be discussed and the overlap between asthma and COPD will be considered, before concluding with an interactive panel debate.

Speakers: Eric Bateman, University of Cape Town, Cape Town, South Africa; Alberto Papi, University of Ferrara, Ferrara, Italy; Tim Harrison, Nottingham City Hospital, Nottingham, UK; J. Mark FitzGerald, Institute for Heart and Lung Health, Vancouver, Canada; and William Busse, University of Wisconsin, Wisconsin, USA

Company: AstraZeneca Pharmaceuticals, Inc.

6:30 to 9:30 p.m.
Grand Hyatt Denver: Grand Ballroom (2nd Floor)
The Shifting Landscape of TB Testing: The IGRA Movement

Please join us for an educational symposium discussing the TB-specific interferon-gamma release assays (IGRAs) currently available, and which patients would benefit from testing using an IGRA instead of the TST. Clinical cases from Employee Health, Pulmonology and Infectious Disease also will be presented for discussion.

6:30 p.m. Buffet Dinner Begins
6:45 p.m. Welcome & Introductions
6:50 p.m. IGRA Testing, A Laboratorian’s Perspective
Speaker: Thomas King, MD, PhD, Chief, Pathology and Laboratory Medicine, St. Vincent Hospital, Worcester, MA

7:20 p.m.  Clinical Aspects in the Management of Tuberculosis
Speaker: Juzar Ali, MD, FRCP(C) FCCP, Russell C. Klein Professor of Clinical Medicine, Section of Pulmonary/Critical Care & Allergy/Immunology, Chief Medical Officer, LSU Health, Director, LSUHSC Chest & TB Clinics, Director, LSUHSC-Wetmore TB Clinics, New Orleans, LA

7:50 p.m. The Role of IGRAs in Immunocompromised Patients: Diagnosing Latent or Active TB
Speaker: Roy F. Chemaly, MD, MPH, FIDSA, FACP, Professor of Medicine, Director, Infection Control Section, Director of Clinical Virology, Department of ID/IC/EH, University of Texas MD Anderson Cancer Center, Houston, TX

8:20 p.m. Question & Answer Session
9 p.m. Conclusion of Program

Company: Oxford Immunotec, Inc.

6:30 to 9:30 p.m.
Sheraton Denver Downtown: Grand Ballroom 1 (Tower Building; 2nd Level)
What’s New in Pulmonary Hypertension (PH) Associated with Idiopathic Interstitial Pneumonia (IIP)? New Hope May Be on the Horizon

This dinner symposium will focus on the recognition and diagnosis of IIP-PH and explore emerging research within the field. Renowned experts will cover topics including the prevalence and significance of PH in patients with IIP, the exploratory process of diagnosing PH in IIP, and recent PH-IIP clinical trial findings.

Speakers: Chair: Steven D. Nathan (Chair), Medical Director, Lung Transplant Program, Medical Director, Advanced Lung Disease Program, Inova Fairfax Hospital, Falls Church, VA; Rajan Saggar, MD, Associate Professor of Medicine, Director Medical Intensive Care Unit Lung & Heart-Lung Transplant and Pulmonary Hypertension Programs, David Geffen School of Medicine, UCLA; and Athol U. Wells, MD, Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK

Company: The France Foundation (supported by a grant from Bayer Pharma AG)

6:30 to 9:30 p.m.
Westin Denver Downtown: Confluence Ballroom (Mezzanine Level)
Which COPD Patients Really Need Inhaled Corticosteroids?
(Open to international attendees only)

This symposium will evaluate the benefits and risks of ICS therapy in COPD. Considering the results of recent ICS-tapering studies, the faculty will debate the appropriate use of these agents, rational strategies on how and when they can be withdrawn, and current and future approaches to managing frequently exacerbating patients.

Speakers: Symposium Chair: Professor Christine Jenkins (Australia); Professor Peter M.A. Calverley (UK), Professor Bartolome R. Celli (U.S.), Professor Christine Jenkins (Australia); and Professor Klaus F. Rabe (Germany)

Company: Boehringer Ingelheim Pharma GmbH & Co. KG